Skip to main content
. Author manuscript; available in PMC: 2018 Jun 1.
Published in final edited form as: Clin Cancer Res. 2016 Oct 27;23(11):2681–2690. doi: 10.1158/1078-0432.CCR-16-1467

Table 4.

Cumulative incidence of tumor recurrence accounting for death as a competing risk, with hazard ratio adjusted for patient age and gender

Variable Hazard Ratio 95% Confidence Interval p-value

ALDH-positive CTC 3.4 1.16, 9.76 0.03

Number of cells: ALDH positive CTC 1.00 0.94, 1.06 0.93

Cytokeratin-positive only CTC 0.8 0.32, 2 0.64

Number of cells: PanCK+ only 1.18 0.83, 1.68 0.36

Triple Positive (cytokeratin, CD133, CD44) CTC 6.45 2.12, 19.65 < 0.01

Number of cells: Triple positive 1.76 1.16, 2.65 0.01

Cytokeratin-positive, CD133 positive CTC 3.24 1.22, 8.62 0.02

Number of cells: PanCK+/CD133+ 0.98 0.78, 1.21 0.83

Positive Lymph Nodes 3.4 1.15, 10.0 0.03

Perivascular Invasion 2.33 0.98, 5.56 0.06

ALDH Stain

 Weak Ref Ref Ref

 Moderate 1.01 0.45, 2.28 0.98

 Strong 0.997 0.35, 2.7 0.96

ALDH as intense as controls 0.69 0.3, 1.59 0.39

Total bilirubin level 1.33

Positive Margin 1.6 0.65, 3.97 0.31

Tumor Grade

 Well/Moderate Ref Ref Ref

 Poor 1.5 0.72, 3.3 0.27

Perineural Invasion 2.6 0.9, 7.6 0.08

Tumor > 3 cm 1.5 0.69, 3.22 0.31

Neoadjuvant Chemo 1.6 0.74, 3.4 0.23

Adjuvant Chemo 1.58 0.24, 10.55 0.63